Distribuzione geografica
Continente #
EU - Europa 4.296
Totale 4.296
Nazione #
IT - Italia 4.296
Totale 4.296
Città #
Genova 2.934
Rapallo 777
Genoa 585
Totale 4.296
Nome #
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 133
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 131
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma 130
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 129
Personalized medicine in allergy 122
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 119
The safety of monoclonal antibodies in asthma 118
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 117
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation 115
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 113
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 113
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases 110
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations 108
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis 107
Current insights in allergen immunotherapy 106
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma 103
The path to personalized medicine in asthma 102
Biosimilars in allergic diseases 102
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? 101
Multiple pulmonary nodules and unexplained fever: when the pulmonologist fails. 100
Umeclidinium for the treatment of uncontrolled asthma 100
Update on immunotherapy for the treatment of asthma 92
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment 85
Severe asthma, biologicals, and auto-injection: Yes, no, may be! 84
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19 84
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials 84
30 Years Of Sublingual Immunotherapy 80
One year of mepolizumab. Efficacy and safety in real-life in Italy 79
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 78
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies 74
The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with Mepolizumab in real life 74
Biologicals for severe asthma: what we can learn from real-life experiences? 70
Mepolizumab in severe asthma: evidence in real-life 69
Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy 68
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs 65
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 65
Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study 59
Evolving phenotypes to endotypes: is precision medicine achievable in asthma? 58
Impact of tDCS on persistent COVID-19 olfactory dysfunction: a double-blind sham-controlled study 56
null 51
Biological agents for severe asthma: the evolution of the at-home self-injection approach. 48
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity 46
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 45
Minimal clinically important difference for asthma endpoints: An expert consensus report 44
FEV6 assessment in spirometric abnormalities screening: the first population-based study in Italian pharmacies 41
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 41
Application of bioendoscopy filters in endoscopic assessment of sinonasal Schneiderian papillomas 41
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 38
Anti-il5 therapies for severe eosinophilic asthma: Literature review and practical insights 36
Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy 25
Severe asthma: One disease and multiple definitions 25
Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies 25
Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma 20
Cerebrospinal Fluid Leak Repair: Usefulness of Intrathecal Fluorescein for Correct Topographic Identification of the Skull Base Defects 19
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center 18
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab 16
Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study 16
Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report 16
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 15
Biologics for the Treatments of Allergic Conditions: Severe Asthma 13
Real-life studies in allergen immunotherapy 13
Do the current guidelines for asthma pharmacotherapy encourage over-treatment? 12
Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85 12
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life 11
Personalizing the approach to asthma treatment 11
Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports 10
Real-life studies of biologics used in asthma patients: key differences and similarities to trials 9
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 9
Quick Olfactory Sniffin’ Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients 8
COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy 7
Nasal cytology as a reliable non-invasive procedure to phenotype patients with type 2 chronic rhinosinusitis with nasal polyps 5
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus 4
Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach 4
Specific Therapy for T2 Asthma 3
Severe chronic rhinosinusitis treated with dupilumab, a real-life analysis of early effectiveness 3
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders 3
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 3
Impulse oscillometry defined small airway dysfunction in asthmatic patients with normal spirometry: Prevalence, clinical associations, and impact on asthma control 3
Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review 3
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 3
null 2
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy 2
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis 1
Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps 1
COVID-19, Eosinophils, and Biologicals for Severe Asthma 1
The new indications for biologicals in type 2 diseases: perspectives 1
Diagnostic therapeutic assistance pathway (PDTA) of type 2 chronic rhinosinusitis 1
Efficacy and steroid-sparing effect of benralizumab: Has it an advantage over its competitors? 1
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses 1
Totale 4.489
Categoria #
all - tutte 13.970
article - articoli 13.816
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.786

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019204 0 0 0 0 0 4 0 1 0 31 85 83
2019/20201.304 39 19 45 124 126 160 204 127 142 161 122 35
2020/2021716 31 45 51 58 65 39 38 61 42 91 46 149
2021/2022595 21 11 17 63 15 72 23 130 53 76 14 100
2022/2023938 67 77 8 72 89 127 73 82 160 58 100 25
2023/2024460 45 92 15 89 52 167 0 0 0 0 0 0
Totale 4.489